Tag Archives: juno

Juno Therapeutics Gets Lift From Cancer Test Results

Juno Therapeutics’ (JUNO) stock rebounded Tuesday as the company reported “highly encouraging” results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat leukemia and lymphoma, using what is called CAR-T therapies, short for chimeric antigen receptor T-cell therapy. CAR-T uses human T-cells as therapeutics to recognize and kill cancer cells, with the

Juno Therapeutics Comments On Cancer Cure Lifts Group

Enthusiasm about potential cancer cures sent shares of Juno Therapeutics (JUNO) and its peers flying Thursday, though Juno’s fourth-quarter earnings late Wednesday missed Wall Street estimates by a lot. “Within the next 12 months, we expect to have 10 product candidates in clinical development directed at six different cancer-associated antigens,” Juno CEO Hans Bishop said in the company’s earnings press release. Juno stock was up 15% in afternoon

Hot Biotech Juno Therapeutics Burning Through Cash

Juno Therapeutics (JUNO), which set a record as the most highly valued biotech IPO of 2014, reported fourth quarter earnings late Wednesday that missed Wall Street estimates by a wide margin. Juno is developing cellular immunotherapies to treat leukemia and lymphoma. It uses human T-cells as therapeutics to recognize and kill cancer cells. The company says that its technology has the potential to revolutionize the way cancer is treated. Juno